Topical gel proves safe, effective treatment for patients with skin t cell lymphoma

Results of a phase one trial show that an investigational topical drug, resiquimod gel, causes regression of both treated and untreated tumor lesions and may completely remove cancerous cells from both sites in patients with early stage cutaneous T cell lymphoma (CTCL) – a rare type of non-Hodgkin lymphoma that affects the skin. Currently, there is no cure for CTCL aside from a bone marrow transplant. However, the new study shows that the topical gel can eliminate malignant T cells, leading to diminished lesions.
Source: ScienceDaily Headlines - Category: Science Source Type: news